Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 9401
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2013  |  Volume : 61  |  Issue : 4  |  Page : 187

Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetic retinopathy-Comment


Clinical Biochemistry, Apollo Speciality Hospitals, Chennai, India

Date of Web Publication17-May-2013

Correspondence Address:
Sachidanandam Vivekanandan
Clinical Biochemistry, Apollo Speciality Hospitals, 322, Anna Salai, Chennai-600 035
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.112172

Rights and Permissions

How to cite this article:
Vivekanandan S. Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetic retinopathy-Comment. Indian J Ophthalmol 2013;61:187

How to cite this URL:
Vivekanandan S. Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetic retinopathy-Comment. Indian J Ophthalmol [serial online] 2013 [cited 2020 Feb 23];61:187. Available from: http://www.ijo.in/text.asp?2013/61/4/187/112172

Sir,

I read the article "Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetic retinopathy" published in your journal Jan-Feb 2012 issue [1] with interest and I offer following comment.

The authors report unique (risk factor) finding of "higher serum total High Density Lipoprotein-cholesterol (HDLC) level", in diabetic (retinopathy) patients.

Currently, the residual risk of coronary events, despite aggressive LDL lowering therapy, results in renewed interest in serum total HDLC. Serum Total HDLC is a complex and heterogeneous in terms of size, shape, electrophoretic mobility, and composition of protein, cholesterol, triglyceride, and phospholipids, where each particle plays different roles such as anti-atherogenic due to reverse cholesterol transport [2] and other roles. Thus not all raised total serum HDLC are equally anti-atherogenic emphasizing HDLC particle composition rather than total HDLC, as an important determinant of its specific functional property (and role) as agreed by the expert clinical lipidologists. [1] Moreover, the inverse correlation between serum HDLC concentration and risk of CHD (Coronary Heart Disease) and decreased cardiovascular (CVD) risk with increasing HDLC levels have been known for years, particularly South Asians are not only notorious to have lower HDLC levels but also have a higher concentration of small, decreased-cardio-protective HDL particles. [3],[4]

Additionally appropriate risk classification of patients based on the established cut points mandates the use of accurate methods for HDLC measurement. The NCEP (National Education Programme) measurement goal is total error [combines imprecision (random error) and inaccuracy or bias (systematic error), represents the maximum tolerable error in measurement of a single specimen] within 13% of the true value. At low HDLC values, this proportional target becomes difficult to achieve. (For example, at 25 mg/dL the proportional goal would be ±1 mg/dL). A recent report on comparative study of performance where most of the currently used HDLC assays across the United Kingdom (UK) laboratories reveals clinically unacceptable overestimation (positive bias ranging up to +32%) and this is worse when processing samples with even moderate amounts of triglycerides, [5] justifying that many of the currently available (homogeneous) assays cannot be confidently recommended for use in long-term clinical trials and other research applications without thorough validation.

In these contexts, the scientific soundness of the statement "higher serum HDLC levels, a unique (risk factor)" finding requires the evidences of HDLC numbers with its measurement methodology and its validation (including steps to ensure optimal long-term stability of those results), which are missing (in this evidence based era) not only in this paper even in their methodology published in the Ophthalmic Epidemiology in 2005 as referred by the authors.

 
  References Top

1.
Damkondwar DR, Raman R, Suganeswari G, Kulothungan V, Sharma T. Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetes retinopathy. Indian J Ophthalmol 2012;60:45-8.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Mackness B, Mackness M. High-density lipoprotein: Why all the fuss? Ann Clin Biochem 2009;46(Pt 1):5-7.  Back to cited text no. 2
    
3.
Bhalodkar NC, Blum S, Rana T, Bhalodkar A, Kitchappa R, Kim KS, et al. Comparison of levels of large and small high-density lipoprotein cholesterol in Asian Indian men compared with Caucasian men in the Framingham Offspring Study. Am J Cardiol 2004;94:1561-3.  Back to cited text no. 3
[PUBMED]    
4.
Superko HR, Enas EA, Kotha P, Bhat NK, Garret B. High-density lipoprotein subclass distribution in individuals of Asian Indian descent: The National Asian Indian Heart Disease Project. Prev Cardiol 2005;8:81-6.  Back to cited text no. 4
    
5.
Cramb R, French J, Mackness M, Neely RD, Caslake M, McKenzie F. Lipid external quality assessment: Commutability between external quality assessment and clinical specimens. Ann Clin Biochem 2008;45:260-5.  Back to cited text no. 5
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed1135    
    Printed10    
    Emailed0    
    PDF Downloaded102    
    Comments [Add]    

Recommend this journal